EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine whether, in patients with symptomatic,
advanced heart failure due to left ventricular systolic dysfunction, treatment with LCZ696
for 24 weeks will improve Pro-B-type Natriuretic Peptide (NT-proBNP) levels, which reflect
hemodynamic and clinical status, compared to treatment with valsartan.
Phase:
Phase 4
Details
Lead Sponsor:
Duke University
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan